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TNO Nutrition and Food Research, Department of Target Organ Toxicology, Working Group Experimental Immunology, Zeist, The
Netherlands
Food allergy is an area of growing interest for
several reasons. First, although evidence is sci-
entiﬁcally insufﬁcient for proof, there are indi-
cations that the number of individuals
suffering from food allergy is increasing.
Second, it is anticipated that for rapid develop-
ments in biotechnology, which will result in
the introduction of new proteins and new bio-
logic varieties for application in food, the
potential allergenicity will pose a major addi-
tional concern in their safety assessment. The
ﬁrst structured approach to assess the potential
allergenicity of novel proteins was the decision
tree jointly prepared by the International Food
Biotechnology Council (IFBC) and the
International Life Science Institute (ILSI)
Allergy and Immunology Institute (Metcalfe et
al. 1996). The various elements of this decision
tree provide important and relevant informa-
tion on suspected characteristics of the protein
related to allergy. However, because no widely
accepted animal models were available at that
time, the IFBC/ILSI decision tree did not
include animal testing procedures, although its
importance was stressed (Metcalfe et al. 1996).
Nevertheless, it is clear that only this kind of
testing will allow direct determination of the
(relative) sensitizing potential of existing and
novel proteins. An Expert Consultancy
on Allergenicity of Foods Derived from
Biotechnology, formed under the auspices of
the Food and Agriculture Organization (FAO)
and World Health Organization (WHO),
released a revised decision tree approach in
2001 (FAO/WHO 2001), which includes the
introduction of animal models. As mentioned
in the conclusions of that report, validation of
these animal models is still an ongoing process.
The Codex Open-Ended Working Group on
Allergenicity, which convened in Vancouver,
British Columbia, Canada, 10–12 September
2001, suggested therefore that animal models
be again labeled as “Areas requiring further
development” (Codex 2001); this document
indicates that “the use of animal models, once
developed and validated, could enhance the
weight of evidence used” (p. 8). Along with
these discussions, research is proceeding by
various groups to make progress in the
development of suitable animal models.
In this article we summarize information
concerning the progress made in a new rat
model for allergenicity testing. The results
obtained up to now indicate that this Brown
Norway (BN) rat model is likely to become a
valuable tool, not only for the improvement of
our knowledge on food allergy in general, but
also for the assessment of the allergenic poten-
tial and potency of genetically engineered
foods.
Food Allergy Model in BN Rats
To study the sensitizing potential of new
proteins, animal models need to satisfy several
important criteria (Penninks and Knippels
2001; Taylor and Lehrer 1996), which are
not easy to achieve in one single model.
Important criteria to consider are selection of
species and strain, production of a Th2
response [resulting in immunoglobulin (Ig) E
production], tolerance to most food proteins,
route of exposure for sensitization and chal-
lenge, and the use of adjuvants. Because pre-
liminary studies at our institute showed
promising results in the rat, we started to
develop an oral feeding protocol to sensitize
rats to food proteins. Comparative sensitiza-
tion studies with Wistar, Piebald Virol Glaxo
(PVG), Hooded Lister, and BN rats, using
ovalbumin (OVA), a well-defined egg-white
allergen, as a first model allergen, revealed
that only the BN rats developed OVA-spe-
cific IgE antibodies (Knippels et al. 1999b).
This is in line with the knowledge that the
BN rat is a high-immunoglobulin (particu-
larly IgE) responder strain and thus, to a cer-
tain degree, resembles atopic humans in their
genetic predisposition to react more readily
with an IgE production to antigens. Because
of this preferential response and the results
obtained in the comparative study, the BN
rat was chosen for the further development of
an oral sensitization model (Knippels et al.
1998b). In subsequent studies (Knippels et al.
Unpublished data), a whole food [cow’s milk
(CM)], whole protein extracts of hen’s egg
white (HEW) and peanut, and purified
strong-allergenic (Arah1 from peanut and
Pen a1 from shrimp), weak-allergenic (Sol t1
from potato tuber), and nonallergenic (beef
tropomyosin) proteins were also used.
A critical factor that heavily affects the
result of oral sensitization studies is the
unscheduled dietary pre-exposure of test ani-
mals and their parental generation to the
antigen under investigation. When oral sen-
sitization studies with proteins are per-
formed, one must ensure that at least two
generations of animals are bred on a diet free
of the antigen under investigation for the
animals to be immunologically naive. It has
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The need for widely accepted and validated animal models to test the potential allergenicity and
potency of novel (biotechnology-derived) proteins has become an important issue for their safety
evaluation. In this article, we summarize the results of the development of an oral sensitization
protocol for food proteins in the rat. Young Brown Norway rats were exposed to either various
puriﬁed allergenic proteins (e.g., ovalbumin, partly puriﬁed), a whole food (cow’s milk), or total
protein extracts (hen’s egg white, peanut) by daily gavage dosing during 42 days without the use
of an adjuvant. The results showed that Brown Norway rats can be sensitized orally to the various
allergenic food proteins tested, resulting in antigen-specific immunoglobulin (Ig) G and IgE
responses, without the use of adjuvants. Animals orally exposed to cow’s milk or total protein
extracts of egg white also developed speciﬁc IgE and IgG antibodies that recognized the same pro-
teins compared with antibodies from patients allergic to egg white or cow’s milk. We also studied
local and systemic immune-mediated effects. In ovalbumin-sensitized rats, some clinical symptoms
of food allergy were studied upon an oral challenge with ovalbumin. The results demonstrated
that gut permeability was increased and that in some animals breathing frequency and systolic
blood pressure were temporarily decreased. The results obtained show that the Brown Norway rat
provides a suitable animal model for food allergy research and for the study of relative allergenicity
of existing and novel food proteins. Key words: allergic potential, Brown Norway rats, challenge
effects, egg-white proteins, food allergy, food proteins, IgE, milk proteins, oral sensitization, oval-
bumin, passive cutaneous anaphylaxis. Environ Health Perspect 111:233–238 (2003). [Online
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21 January 2003]been shown that exposure of the parental
generation to the antigen under investigation
can influence the outcome of sensitization
studies with the offspring (Knippels et al.
1998a).
In the sensitized BN rats, we also studied
whether, upon renewed oral antigen exposure
challenge, clinical reactions could be observed
as are those in food-allergic patients upon
exposure to the offending food. The many
different clinical signs or physiologic reactions
observed upon renewed oral antigen exposure
in food-allergic patients frequently include
effects on gastrointestinal physiology, whereas
only in some patients are effects on the respi-
ratory and/or cardiovascular system noted.
Therefore, in OVA-sensitized rats, oral chal-
lenges were performed by intragastric intuba-
tion 10 days after the oral sensitization period
of 42 days, with doses of OVA varying
between 10 and 100 mg. As part of the oral
challenge, effects on blood pressure, gastroin-
testinal permeability, and breathing frequency
were investigated (Knippels et al. 1999a).
Materials and Methods
Proteins. The various different antigen
sources used in the oral sensitization studies
were either prepared or obtained from differ-
ent suppliers. The total HEW protein extract
was prepared essentially according to the
method of Bernhisel-Broadbent et al. (1994).
A more detailed description of the prepara-
tion of this protein extract is given by
Knippels et al. (2000). Other antigen sources
used were OVA (Fluka Chemie, Buchs,
Switzerland; purity, 70%) and skimmed CM
(Albert Heijn, Zaandam, The Netherlands;
4g   protein/100 mL milk). The puriﬁed pro-
teins used—Arah1, Sol t1, Pen a1, and beef
tropomyosin—were purified from their
native foods (peanut, potato tuber, raw
brown shrimp, and raw beef, respectively).
Verification of purity and identity were fol-
lowed by SDS-PAGE and N-terminal
sequencing or MALDI TOF, respectively.
Ara h1 (molecular weight, 60–67 kDa;
purity, 88.0%), Sol t1 (molecular weight
40–43 kDa; purity, 92.6%), Pen a1 (molecu-
lar weight, 37–38 kDa; purity, 94.6%), and
beef tropomyosin (molecular weight,
35–39 kDa; purity, 99.3%) were prepared by
Gary Bannon et al. (Unpublished data).
Rats. For the sensitization studies, young
male BN rats, 4–6 weeks old at study initia-
tion, were obtained from Charles River
(Sulzfeld, Germany). The rats were housed
in an animal room maintained at 23 ± 3°C,
with a light/dark cycle of 12 hr each and a
relative humidity of 30–70% during the
experiment and for at least 10 days before
study initiation. The animals were housed in
stainless-steel wire cages in groups of four or
five and had free access to food and tap
water. The rats were bred and raised on a
commercially available rodent diet that was
HEW-protein and CM-protein free (SDS
Special Diet Service, Witham, England).
Prestudy blood samples were always tested
for HEW-, CM-, and peanut-protein–spe-
ciﬁc antibodies to ensure the use of immuno-
logically naive animals with respect to the
antigens under investigation. All animal
studies were approved by an independent
ethical committee.
Oral sensitization protocol. In the ultimate
standard protocol used for most studies, the
BN rats were exposed to the various proteins
or protein extracts by daily gavage dosing,
using a 18-gauge stainless steel animal feeding
needle (standard dose is 1 mg protein/mL tap
water, 1 mL/animal) during 6 weeks, without
the use of an adjuvant. Blood samples were
obtained from the orbital plexus under light
CO2 anesthesia at weekly intervals or by exsan-
guination from the abdominal aorta at sacri-
fice. After coagulation for 1 hr at room
temperature, the blood samples were centri-
fuged (Heraeus Minifuge T, Osterode, Ger-
many) for 20 min at 2,000 g and 4°C to
obtain sera. The sera were stored at –20°C
until analyses for antigen-speciﬁc IgG titers by
enzyme-linked immunosorbent assay (ELISA)
and antigen IgE by ELISA and passive cuta-
neous anaphylaxis (PCA) test in naive rats.
Assays for antigen-specific IgG and IgE
antibodies. Serum antibodies (IgG, IgE)
specific for the various allergenic proteins
(extracts) tested were measured by ELISA.
The procedures used to detect specific IgG
and IgE antibodies to the puriﬁed proteins or
protein extracts are described in detail in pub-
lications by Knippels et al. (1998a, 1998b,
1999a, 1999b, 2000). In summary, for the
detection of antigen-specific IgG, 96-well
microtiter plates (flat-bottomed; Maxisorp,
NUNC, Roskilde, Denmark) were coated
overnight at 4°C with 100 µL/well of the
antigen in carbonate buffer, pH 9.6. After
three washing steps with tap water containing
0.4% Tween 20 (Merck, Hohenbrunn,
Germany), 100 µL/well phosphate-buffered
saline (PBS) containing 1% bovine serum
albumin (BSA; Sigma Chemicals Co., St.
Louis, MO, USA) and 0.02% Tween 20
(PBS/BSA-Tween 20) was added. After 1 hr
incubation at 37°C, the plates were washed,
and serial dilutions of rat serum in PBS/BSA-
Tween 20 were added to the wells and
incubated for 1 hr at 37°C. After washing,
100 µL/well peroxidase-conjugated goat anti-
rat IgG (H+L) (Zymed, San Francisco, CA,
USA; diluted 1:500) in PBS/BSA-Tween 20
was added. After incubation for 1 hr at 37°C,
the plates were washed again, and an enzyme
substrate solution of 3,3´,5,5´-tetramethyl-
benzidine (TMB; Sigma Chemicals;
100 µL/well; 6 mg/mL dimethyl sulfoxide)
was added. The plates were developed at
room temperature for 5–15 min. Finally,
100 µL/well of 2N H2SO4 was added.
Optical densities were read spectrophotome-
trically at 450 nm with an ELISA plate reader
(Microplate Reader, Bio-Rad Laboratories,
Richmond, VA, USA). Positive and negative
control samples were incorporated for each
96-well plate. A preserum pool was used as
negative control. The pooled preserum was
measured at a 1:4 dilution. The average
extinction in negative control wells, to which
three times the standard deviation was added,
provided the reference value taken to deter-
mine the titer in the test sera. Each test serum
was titrated starting at a 1:4 dilution, and the
reciprocal of the greatest serum dilution giv-
ing an extinction higher than the reference
value was read as the titer. All analyses were
performed in duplicate.
For the detection of antigen-speciﬁc IgE,
96-well microtiter plates were coated overnight
at 4°C with 100 µL/well mouse anti-rat IgE
(MARE-1, Zymed) at a concentration of 1.5
µg/mL in carbonate buffer, pH 9.6. The plates
were washed, and 100 µL/well of PBS/BSA-
Tween 20 was added. After incubation for 1 hr
at 37°C, the plates were washed and diluted rat
serum samples were added and incubated for 2
hr at 37°C. The plates were washed, and then
100 µL/well of a solution of an antigen-digoxi-
genin (Boehringer, Mannheim, Germany)
conjugate was added as prepared according to
the manufacturer’s instructions. Incubation
with antigen-digoxigenin was performed for 1
hr at 37°C, and after washing, 100 µL/well
peroxidase-conjugated sheep anti-digoxigenin
Fab fragments (Boehringer) diluted 1:3,000 in
PBS/BSA-Tween 20 was added. After incuba-
tion for 1 hr at 37°C, the plates were washed
again, and an enzyme substrate solution of
TMB was added. Plate development, measure-
ment, and titer elaboration were as described
for the OVA-speciﬁc IgG ELISA.
Passive cutaneous anaphylaxis. To conﬁrm
the presence or absence of anaphylactic anti-
bodies, rat sera were also tested by PCA essen-
tially as described previously by Ovary (1964).
In short, naive (untreated) BN rats were
shaven on the back and flanks and injected
intradermally with 0.1 mL of the test serum in
serial dilutions, followed 64 hr later with an
intravenous injection of 1 mL of a 1:1 mixture
of a solution of the protein or protein extract
studied (5 mg/mL sterile saline) and a solution
of Evans blue (2% in sterile saline). After
20–30 min, the diameter of dye extravasation
at the site of the serum injection was mea-
sured. The reaginic titer was read as the recip-
rocal of the greatest dilution giving a colored
spot of at least 5 mm in diameter. Positive and
negative control sera as used in the ELISAs
were assayed simultaneously with the test sera
on each animal used for the PCA tests.
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The procedures used for the detection of the
respiratory function, blood pressure, and gut
permeability on an oral challenge of sensi-
tized rats are described in detail elsewhere
(Knippels et al. 1999a). Main characteristics
are presented brieﬂy here.
Respiratory function. Both control and
OVA-sensitized animals were orally chal-
lenged with 2 mL of increasing doses of an
OVA solution in tap water. Respiratory fre-
quency was assessed using a plethysmograph
with a separate head and body chamber and
matched pressure transducers. Rats were
restrained in tubes placed in the body cham-
ber with the open end of the tube ﬁtting into
the front chamber. Breathing frequencies were
determined by recording the pressure signal in
the volume-calibrated body chamber. Before
challenge, the respiratory function was mea-
sured constantly for 15 min and immediately
upon an oral challenge with OVA constantly
during the ﬁrst 10 min and thereafter for peri-
ods of 30 sec once every 5 min for a total
period of 6 hr.
Blood pressure. During the sensitization
period, the rats were trained to get used to the
measurement equipment (an inflatable pres-
sure cuff around the tail and a distal taped
sensor) to avoid stress during the experi-
ments. The control and the OVA-sensitized
animals were orally challenged with 2 mL of a
5 mg/mL OVA solution in tap water or 2 mL
of tap water. Subsequently, the systolic blood
pressures were recorded at intervals during a
period of 7 hr.
Gut permeability. To determine possible
changes in gut permeability, the uptake of a
bystander protein was determined in time
after the challenge. Control and OVA-sensi-
tized animals were orally challenged with
2 mL tap water or 2 mL of an OVA solution
in tap water. The animals received an addi-
tional intragastric dose of β-lactoglobulin
(β-LG; 1 mL of a 100 mg/mL solution in
tap water) 30 min after the oral OVA chal-
lenge. Blood samples were collected from
the orbital plexus under light CO2 anesthe-
sia at various time points after the β-LG
administration. Sera were used for the
quantiﬁcation of β-LG by ELISA.
Results
Oral sensitization effects. Our studies have
shown that BN rats, bred and raised on a diet
free of the antigen to be tested, can be sensi-
tized by daily dosing with the antigen via the
enteral route without the use of adjuvants.
The standard protocol used is based on the
results of various studies with mainly OVA as
allergen. In these studies, not only the mode
of application (gavage vs. ad libitum in drink-
ing water) but also the dose (0.002, 0.02, 0.2,
2, or 20 mg OVA/dose) and the frequency of
application (daily, twice a week, once a week,
once every 2 weeks) were studied (Knippels et
al. 1998b). These studies revealed that the
best results were obtained from daily intragas-
tric dosing with 1 mg OVA during 42 days.
Besides OVA-speciﬁc IgG, OVA-speciﬁc IgE
antibody responses were found in these ani-
mals as measured by ELISA and PCA.
Optimal OVA-specific IgE antibody
responses were observed around days 28–35.
The percentage of IgE responders in our
OVA studies in general exceeded 80%.
However, occasionally, no OVA-speciﬁc IgE
responses were induced upon daily gavage
dosing with OVA in our studies. Less fre-
quent administration of 1 mg OVA by gav-
age, once a week or once every 2 weeks, did
not induce specific IgG or specific IgE anti-
body responses. Upon gavage dosing twice a
week for 6 weeks with 1 mg OVA, only one
of four animals developed an OVA-specific
IgG and IgE response. Ad libitum exposure to
OVA in the drinking water resulted in only
OVA-speciﬁc IgG, and no OVA-speciﬁc IgE
was detected. Recent studies by Akiyama et
al. (2001) demonstrated, however, that their
OVA-dosing regime in the drinking water
produced OVA-specific IgE titers, although
they confirmed that daily gavage dosing of
BN rats showed higher OVA-specific IgE
titers. That the BN rat was indeed the most
suitable strain for oral sensitization studies
was confirmed in comparative studies using
different strains of rats (Knippels et al.
1999b). Upon oral exposure of Wistar, PVG,
Hooded Lister, and BN rats to OVA, it was
apparent that only BN rats developed OVA-
specific IgE antibodies. Subsequent studies
(Knippels et al. 2000), using daily gavage dos-
ing of the animals for up to 9 weeks to vari-
ous concentrations (0.5, 1, 2.5, 5, 10, and
15 mg protein/mL/day) of OVA, HEW-pro-
tein extract, or CM, showed the best results
in specific IgG antibodies at a dose of 1 mg
OVA/mL/day versus 10 mg for HEW and
CM protein/mL/day (Figure 1A–C). Clear
OVA-specific IgE titers were also observed
(Figure 1D). Because it is technically not pos-
sible to measure CM and HEW protein-spe-
cific IgE responses by ELISA, reaginic
antibody responses were detected by PCA.
However, despite observation that by
immunoblotting the sera of HEW- and CM-
sensitized rats showed IgE antibodies to the
main allergens in HEW and CM, only a low
number of IgE responders were observed as
measured by PCA. An explanation for this
apparent discrepancy may be that the HEW
and CM IgE titers were not high enough to
be measured by PCA, because it was shown
in previous studies that the PCA was less
sensitive than ELISA (Knippels et al. 1998b).
An important observation for the BN rat
model was that the profile of allergens
recognized by the immune system of the BN
rat appeared comparable with the profile of
allergens recognized by allergic patients.
Specific IgG antibodies in sera from both
HEW-allergic patients and rats orally sensi-
tized to HEW proteins recognized a whole
repertoire of proteins, the profile of which
appeared to be the same. Although HEW is a
complex mixture of more than 20 proteins,
the speciﬁc IgE antibodies in sera from both
HEW-allergic patients and rats orally sensi-
tized to HEW proteins recognized the same
proteins (mainly ovotransferrin, OVA, ovo-
mucoid, and to a lesser extent lysozyme), all
claimed to be the major allergens for HEW-
allergic humans (Ebbehoj et al. 1995), and no
reaction was observed against any other pro-
tein present in the HEW-protein extract. The
same phenomenon was observed when the
patterns of protein recognition by antibodies
in sera from rats orally sensitized to CM pro-
teins and antibodies present in sera from
CM-allergic patients were compared. The
induced antibodies were directed mainly
against β-LG and, to a lesser extent, against
the caseins. Although CM contains more
than 30 proteins, no reaction was observed
against any other protein present in CM.
These results indicate that upon daily intra-
gastric dosing with HEW proteins or CM
proteins, the specific protein recognition of
induced antibodies in the BN rat is compara-
ble with that observed in sera from allergic
patients. The same phenomenon was
described in BN rats intraperitoneally sensi-
tized with CM, which produced a profile of
IgE antibodies to milk proteins similar to that
observed in humans (Atkinson et al. 1996).
Although the induced antibodies in the
BN rat apparently react to relevant proteins
comparable with the human situation, it
remains to be elucidated whether the induced
speciﬁc antibodies in the rat react to the same
epitopes as the antibodies in the sera from
patients.
More recently, several oral sensitization
studies were performed in BN rats with crude
raw- or roasted-peanut protein extracts and
with some purified allergenic proteins and
one nonallergenic protein (Knippels et al.
Unpublished data). Between crude raw or
roasted peanut extracts, no clear differences
were observed in the sensitizing potency as
measured by the Th2-mediated IgG2a pro-
duction at dose levels ranging from 0.01 to
10 mg of peanut protein/day. From day 7
onward, the number of positive responders
and the magnitude of the IgG2a response
increased in time. However, at each time
point the magnitude of the IgG2a response
was almost similar in the different dose
groups, indicating the sensitizing potency of
even very low doses of peanut protein. As
measured by PCA, only a limited number of
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three major peanut allergens, Ara h1, Ara h2,
and Ara h3, the IgG2a responses were deter-
mined in sera of rats sensitized orally or
intraperitoneally with peanut proteins. After
intraperitoneal sensitization, the IgG2a anti-
bodies were directed mainly toward Ara h2
and, to a lesser extent, to Ara h1; after oral
sensitization, they were directed against all
three major peanut allergens. This observa-
tion may indicate that upon oral or intraperi-
toneal sensitization, a different sensitization
proﬁle may be induced.
For predictive screening of new proteins, the
assessment of relative allergenicity in animal mod-
els will be a very important aspect in relation to
validation and acceptance. Therefore, a collabora-
tive study with two industrial partners (Monsanto
in the United States and Syngenta in the United
Kingdom) was begun recently using some selected
and puriﬁed allergenic and nonallergenic proteins
(Knippels et al. Unpublished data). We exposed
BN rats by gavage at different dose levels in the
presence and absence of an oral adjuvant. BN rats
were also sensitized intraperitoneally at one dose
level of each protein. Ara h1 (purified from
peanut), Pen a1 (puriﬁed from shrimp), and Sol
t1 (purified from potato tuber) were used as
strong to weak allergens, respectively, and
tropomyosin (puriﬁed from raw beef) as a nonal-
lergenic protein based on human experience. Two
identical studies were performed with these puri-
ﬁed proteins, with animals of different suppliers in
the two studies, and the preliminary results indi-
cated marked differences between these studies.
Despite assurances of the animal suppliers, there
are indications that the different ﬁndings regard-
ing the relative allergenicity of the tested proteins
in the two studies performed were caused by the
unexpected pre-exposure of the animals of the ﬁrst
study to one of the allergens used and to a cross-
reacting allergen. In the second study, the oral sen-
sitizing potential decreased in the order Ara h1 >
Pen a1 > Sol t1, with no sensitization to beef
tropomyosin in both studies.
The probable cause of the different results
obtained in the above-mentioned identical
sensitization studies stresses again that the
unscheduled dietary pre-exposure of the test
animals to the test protein will affect the results
of the sensitization studies. Previous studies
have demonstrated that the exposure of the
parental generation to the antigen under inves-
tigation inﬂuenced the outcome of the sensiti-
zation study with the offspring (Knippels et al.
1998a). BN rats bred and raised on a soy-pro-
tein–containing diet for several generations
were found to have soy-speciﬁc IgG antibod-
ies. These antibodies remained detectable in
serum of the parental animals after feeding for
6 months on a soy-free diet. Even in serum of
their F1 generation of offspring, raised further
on a soy-free diet for periods up to 6–12
month, soy-speciﬁc IgG was still detectable. In
the second, third, and fourth generation of off-
spring, bred and raised on a soy-free diet, no
soy-speciﬁc IgG was detected, and oral sensiti-
zation could be achieved again in these rats. To
get immunologically naive and responsive rats
for oral sensitization studies with proteins, it
will therefore be of importance to ensure that
the rats have been bred and raised for at least
two generations on a diet free of the protein to
be tested.
In summary, the results described support
that the BN rat may provide a suitable animal
model for food allergy research and to study
the relative allergenicity of (novel) food
proteins.
Challenge effects. To characterize the
developed BN rat model in more detail, addi-
tional studies were performed to investigate
local and systemic immune-mediated effects
upon enteral challenge and to study mecha-
nisms involved in sensitization (Knippels et
al. 1999a). The possible occurrence of local
and systemic effects upon an oral challenge
was investigated in OVA-sensitized animals
by monitoring gut permeability, and respira-
tory functions and blood pressure, respec-
tively. On an oral challenge with OVA, gut
permeability was increased as evidenced by an
increased uptake of a bystander protein 
(β-LG). One hour after an OVA challenge
followed by an oral dose of β-LG 30 min
later, the amount of β-LG in the sera of pre-
viously sensitized rats was signiﬁcantly higher
compared with nonsensitized animals
(Figure 2). Several models of intestinal hyper-
sensitivity to food proteins have shown that
antigen challenge of the sensitized intestine
causes alterations in ion transport, permeabil-
ity, and motility (Berin et al. 1997; Crowe
and Perdue 1992) and in the release of
mediators in anaphylactic reactions such
as histamine, platelet-activating factor,
prostaglandins, and leukotrienes and in the
release of some newly formed cytokines that
have been shown to alter mucosal function in
experimental models (Heyman et al. 1994;
Kanwar et al. 1994). However, up to now it
has not been fully revealed whether the
increased macromolecular passage is mainly
due to transcellular or paracellular transport.
Despite this, our finding that a significant
amount of intact β-LG is present in sera of
sensitized animals—together with the ﬁndings
of Scudamore et al. (1995) who showed that
the release of rat mast cell protease II, a known
rat mucosal mast cell mediator, increases
epithelial permeability via a paracellular
route—suggests an increased epithelial perme-
ability in our animals via a paracellular route,
although an increased permeability via the
transcellular route cannot be excluded.
In addition to studies on local effects, the
possible occurrence of systemic effects upon
an oral challenge were studied by measuring
the breathing frequency and systolic blood
pressure. These studies revealed that an oral
challenge with OVA did not induce a clear
effect on the respiratory system or blood pres-
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Figure 1. Time dependency of IgG responses speciﬁc to (A) OVA, (B) HEW protein, (C) CM protein, and (D)
the OVA-specific IgE responses in young BN rats upon daily intragastric dosing with 1 mg OVA, 10 mg
HEW protein, or 10 mg CM protein per rat each day for 63 days. Immunoglobulin titers were determined in
blood samples obtained at weekly intervals. The data are presented as mean 2log IgG/IgE titer ± SD of six
rats/group. The numbers of responders at the respective time points are indicated in the bars.
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C Dsure in most animals. However, some animals
demonstrated a temporary decrease in breath-
ing frequency or systolic blood pressure.
These observations indicate that systemic
effects can be induced in orally sensitized ani-
mals on an oral challenge. In literature, a
drop in breathing frequency below 70% of
the normal breathing frequency is considered
an indication of severe respiratory effects
(Botham et al. 1989). Although we observed
severe respiratory effects in only a few animals
(~10–15% of the animals), this low incidence
agrees with observations from food allergic
patients, of whom only about 10% react with
respiratory problems (Monteleone and
Sherman 1997). In several animals (~40% of
the animals), a decrease in systolic blood pres-
sure was observed, but no dramatic drop in
blood pressure, resulting in circulatory col-
lapse, was observed. Again, the rather low
incidence of cardiovascular effects upon oral
challenge of the rats is in accordance with the
human clinical practice.
Conclusion
It is evident that for assessment of the
potential oral allergenicity of “novel pro-
teins,” new appropriate approaches are nec-
essary. In this context, the development of
predictive animal models is often indicated
as urgently needed. In such predictive and
widely accepted animal models, products
with an unknown history of allergenicity or
those that show one or more physicochemi-
cal characteristics of known allergens can be
studied to demonstrate the ultimate proof
for the presence or absence of sensitizing
activity of the novel protein. In the past few
years, several groups have studied animal
models related to food allergy research.
Studies in mice have shown that upon
repeated enteral protein administration in
combination with adjuvants, immune prim-
ing or sensitization can be achieved (Ito et
al. 1997; Li et al. 1999, 2000). For assess-
ment of potential allergenicity, the intraperi-
toneal route of exposure is also studied in
mice (Hilton et al. 1997; Dearman et al.
2000 ; Kimber et al. 2000). Appropriate
domestic models that are considered to be
useful models to predict the potential aller-
genicity of novel proteins or that can pro-
vide comprehensive understanding of
IgE-mediated disease mechanisms are the
atopic dog model (Ermel et al. 1997) and
the swine model (Helm et al. 2002). For the
rat, studies on sensitization to food proteins
in the presence of an adjuvant have also
been described (Atkinson et al. 1996;
Atkinson and Miller 1994).
Here we describe an oral sensitization
protocol in BN rats without the use of an
adjuvant (Knippels and Penninks 2002;
Knippels et al. 1998b). These results suggest
that oral exposure to food proteins may pro-
duce a signiﬁcant IgE response to the puriﬁed
proteins. In addition, exposure to a whole
food (CM) or a mixture of proteins (HEW
and peanut-protein extracts) resulted in spe-
cific antibody responses toward several pro-
teins, whereas most proteins present in CM
and HEW extract did not elicit a speciﬁc IgE
response in the BN rat. The profile of aller-
gens recognized by the immune system of the
BN rat appeared comparable with the proﬁle
of allergens recognized by allergic humans as
measured by immunoblotting (Knippels et al.
2000). Along with oral sensitization, we also
showed clinical effects after an oral challenge
in the sensitized animals. We showed limited
systemic effects on respiratory and circulatory
functions and more clear local effects on gas-
trointestinal permeability upon oral OVA
challenge of OVA-sensitized BN rats
(Knippels et al. 1999a).
Although additional studies are needed
with more purified strong and weak aller-
gens, nonallergens, and allergenic whole
foods or their protein extracts, to further val-
idate the developed BN rat model, the results
obtained up to now support the BN rat
model as a useful animal model for studying
oral sensitization to food proteins. This
model is also useful for studying immune-
mediated effects upon oral challenges with
food proteins and to assess thresholds for
challenge reactions in sensitized rats using rat
mast cell protease II, based on the results of
preliminary studies in peanut-protein–sensi-
tized rats (Knippels et al. Unpublished data).
In addition, the model seems promising for
studying mechanistic aspects of food allergy
as well as new prophylactic or therapeutic
interventions for food allergy.
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β-LG in serum samples were followed in time as a measure for gastrointestinal tract permeability. The
OVA-sensitized animals had anti-OVA IgE titers of ≥ 5. Limit of detection is 10 ng/mL.
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